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Purpose or Objective: Childhood cancer survivors (CCS) face 
high risk for late effects. Aside from malignant neoplasms, it 
is known that ionizing radiation induces benign tumours of, 
e.g., the central nervous system and other sites. Record-
linkage with pathology report registries provides a unique 
opportunity to obtain non-selected and uniformly collected 
benign tumour information. We aim to estimate the 
incidence of histologically-confirmed solid benign tumours 
(SBT), to describe clinical characteristics and to quantify the 
role of radiotherapy (RT). 
 
Material and Methods: The Dutch Childhood Oncology Group 
– Late effects after childhood cancer (DCOG LATER) is a 
collaborative effort of all 7 academic paediatric 
hemato/oncology centres in the Netherlands with clinicians 
and researchers who focus on optimal patient care and 
research in CCS. The DCOG LATER cohort includes 6168 five-
yr CCS treated between 1963 and 2001 before the age of 18 
yrs. The entire DCOG LATER cohort was linked with the 
nationwide Dutch Pathology Registry (PALGA) to ascertain 
histologically confirmed SBT (excluding skin) diagnosed 
between 1990-2014. 
 
Results: We identified 1278 eligible pathology reports in 788 
CCS after a median follow up since diagnosis of 22 yrs (max. 
52). We excluded reports on SBT diagnosed within 5 yrs after 
childhood cancer (243 reports); 145 reports without a clear 
diagnosis in conclusion and 25 reports still to be classified. 
These preliminary analyses include 865 reports from 578 CCS, 
of whom 79% had one SBT, and 21% had multiple. Tumour 
locations included head/neck/CNS (36%), chest (13%), 
abdomino-pelvic (34%), and extremities (14%). Of 3% location 
was unclear. Most common SBT types in the head/neck/CNS 
were meningiomas (44%), often following cranial 
radiotherapy (RT) (95%); mammary fibroadenomas (49%), 1 in 
6 after RT chest; colorectal adenoma (38%), including 1 in 4 
after abdominopelvic RT, and female genital tract tumours 
(leiomyomas and ovarian mucinous cystadenomas) (29%), 1 in 
3 after abdominopelvic RT. We will present effects of RT 
dose, chemotherapy and genetic syndromes. 
 
Conclusion: This preliminary analyses give insight into the 
amount and types of histologically confirmed SBT in CCS in 
relation to RT. To our knowledge, this is one of the first 
comprehensive assessments of subsequent SBT among CCS. In 
ongoing clinical follow-up studies we aim to gain knowledge 
about risk factors and clinical characteristics (e.g. 
meningioma) to help guideline groups decide for or against 
screening of asymptomatic, high-risk CCS. 
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Purpose or Objective: Feasibility study for the clinical 
implementation of a hybrid radiation therapy system 
consisting of an MR-on-rails scanner and a linear accelerator. 
 
Material and Methods: A 1.5 T MR-on-rails system (IMRIS, 
Minnetonka, MN) was configured a) to be used as a 
standalone MR simulator in a dedicated suite or b) to travel 
on ceiling-mounted rails to an adjacent linac vault and 
operate in the vicinity of a 6X FF/FFF TrueBeam therapy 
system (Varian Medical System, Palo Alto, CA). The in-room 
MR guidance is intended be used in conjunction with the 
standard linac’s kV imaging for the patient setup verification 
and treatment delivery. Key aspects of the MR and linac 
integration were investigated such as: magnetic field 
coupling of the MR with the linac vault environment, RF 
noise, RT workflows, safety systems, and QC procedures. 
Numerical simulations and measurements were performed to 
establish the magnetic field optimal separation between the 
MR and linac. A FEM-based simulation space was built and 
validated to mimic the full-scale MR-linac/couch system; this 
provided a detailed picture of the magnetic field coupling 
effects and guided the engineering activities. Field mapping 
was performed with low/high field Hall probes, and pull 
forces on couch sub-components were measured via a force 
gauge for several scenarios. Hysteresis effects on the linac 
beam performance were quantified by measuring the 
flatness/symmetry/output vs. gantry angle for short and 
long-term MR’s field exposures. The MR performance was 
evaluated using procedures available in the service mode of 
the MR console as well as dedicated methods developed in-
house (e.g. B0 mapping). RF noise isolation was achieved by 
parking the linac behind specially designed RF doors during 
the MR imaging sessions. An interlocking system was designed 
and implemented to enforce the safe linac curation (e.g. 
gantry position, doors statues and table position) prior to 
MR’s travel into the vault. 
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Results: The MR-linac platform is in the last phase of the 
assessment. At its pre-defined imaging position in the linac 
room, the MR was shimmed and configured to work at peak 
performance. The linac’s radiation beam output was also 
found to be within specifications, being not affected by 
multiple passive exposures (testing over one year) to the 
MR’s magnetic fringe field. A hybrid MR-kV framework is 
under development to enable comprehensive RT tools for MR-
only RT planning, quantification of organ motion (fast 
imaging), in-room treatment guidance, and site specific 
adaptive RT workflows. QC procedures specific to the MR and 
linac integration were also developed for the mapping and 
correction of both scanner-related and patient-induced MR 
image distortions, mutual registration of the MR and linac 
isocenters, B0 mapping for monitoring the MR performance, 
4D MR, and generation of synthetic CT data sets. 
 
Conclusion: Key milestones of the MR and linac integration 
were achieved, supporting the feasibility of the system for 
clinical implementation.  
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Purpose or Objective: Locally advanced lung cancer lacks 
effective treatment options and may require aggressive 
chemo-radiotherapy (RT) with high doses. In the light of the 
RTOG 0617 trial, multi-centre dose escalation trials should 
avoid increasing organ at risk (OAR) toxicity and require strict 
quality assurance (QA). Dose escalation can be performed for 
sub volumes of the tumour by targeting of the most FDG-PET 
avid regions, and the planning target volume (PTV) can be 
reduced by implementing daily soft tissue based image-
guidance and adaptive RT. Incorporating these elements, the 
randomized multi-centre trial NARLAL2 by the Danish 
Oncologic Lung Cancer Group aims at increasing loco-regional 
control at 30 months without increasing toxicity. 
 
Material and Methods: In the standard arm, the PTV is 
treated with a homogenous dose of 66 Gy/33 fractions (fx). In 
the experimental arm, the dose is escalated heterogeneously 
to the FDG-PET avid volumes, with mean doses up to 95 
Gy/33 fx for the most PET active volumes of the primary 
tumour, and 74 Gy/33 fx for malignant lymph nodes ≥ 4 cm3. 
The escalation dose is limited in favour of OAR constraints. A 
standard and an experimental treatment plan are optimized 
for each patient prior to randomization. Dose to the lung in 
the experimental plan is kept similar to the lung dose in the 
standard plan. All enrolment centres were obliged to follow a 
strict QA program consisting of a treatment planning study, a 
soft tissue match and adaptive strategy workshop, and QA for 
PET scanners and FDG-PET volume delineation. In the present 
study, the dose distributions of the first 20 patients are 
analysed. The achieved dose escalation is compared to a 
previously conducted pilot study. 
 
 
 
Results: In the pilot study, the dose escalated FDG-PET avid 
part of tumour (PET GTV-T) and lymph nodes (PET GTV-N) 
received an average mean dose of 91.9 Gy and 72.1 Gy, 
respectively. The combined clinical target volume (CTV-total) 
received an average mean dose of 78.6 Gy. This corresponds 
to a 16 % estimated increase in loco-regional control at 30 
months. For the first 20 patients included, the experimental 
plan achieved an average mean dose of 92.3 Gy (SD 3.7) to 
PET GTV-T. A total of 11 large lymph nodes were escalated to 
an average mean dose of 72.1 Gy (SD 2.7) to PET GTV-N. 
CTV-total obtained an average mean dose of 75.8 Gy (SD 
4.1). Normal tissue doses were similar for the experimental 
and standard plan (Table 1). The maximum dose for the 
standard plans was 72.6 Gy (110%). Higher doses were 
applied for the experimental plans, but only to small volumes 
respecting the strict normal tissue constraints (see figure). 
 
 
 
Conclusion: A dose escalation trial with strict QA has been 
set up. Patient enrolment started January 2015. Analysis of 
the first 20 patients demonstrates that the escalation goals 
were met for the target and that dose to OARs were similar 
for the standard and the experimental treatment plans.  
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